Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP Trial)
Source: View publication →
In older Chinese patients with hypertension, targeting a systolic blood pressure of 110 to less than 130 mm Hg significantly reduced the incidence of major cardiovascular events compared to a standard target of 130 to less than 150 mm Hg.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STEP trial provides robust, confirmatory evidence that intensive systolic blood pressure lowering to <130 mm Hg is both safe and highly beneficial in older adults. It successfully addresses many of the debates triggered by the SPRINT trial by showing similar cardiovascular risk reductions—particularly in stroke and heart failure—using conventional office blood pressure measurements rather than automated unattended measurements, and further justifies the lowering of blood pressure targets for the elderly in modern clinical guidelines.
Historical Context
For decades, blood pressure targets in the elderly were debated due to fears of poor tolerance, polypharmacy, and falls. The landmark SPRINT trial (2015) demonstrated striking mortality and cardiovascular benefits with an intensive target of <120 mm Hg, but faced criticism regarding its specialized automated blood pressure measurement protocol, which did not reflect routine real-world practice, and its lack of generalizability to certain populations. Consequently, major guidelines diverged: the 2017 ACC/AHA guidelines recommended <130/80 mm Hg for most, while European guidelines suggested a more conservative 130-139 mm Hg for older adults. The STEP trial (2021) was launched to evaluate intensive versus standard targets specifically in an older, East Asian population using standard measurement practices, ultimately confirming that lower targets indeed translate to major cardiovascular event reductions.
Guided Discussion
High-yield insights from every perspective
Older patients often develop isolated systolic hypertension due to arterial stiffening. Physiologically, why have clinicians historically been hesitant to aggressively lower systolic blood pressure in the elderly, and what reflexes or perfusion concerns does the STEP trial's safety data help alleviate?
Key Response
Aging causes reduced aortic compliance, leading to high systolic blood pressure (SBP) and low diastolic blood pressure (DBP), known as a wide pulse pressure. Aggressive SBP lowering raised concerns about dropping DBP too low, thereby compromising coronary perfusion (which occurs primarily during diastole), and blunting the baroreceptor reflex, leading to orthostatic hypotension and falls. The STEP trial demonstrated that targeting an SBP of 110 to <130 mm Hg significantly reduced cardiovascular events without an unacceptable increase in syncope, fractures, or major renal outcomes, countering the 'J-curve' hypothesis.
When applying the STEP trial's intensive target (SBP 110 to <130 mm Hg) to an older patient in the clinic, which specific adverse events highlighted by the trial should you monitor most closely, and how might this influence your choice and titration of antihypertensive agents?
Key Response
While severe adverse events like fractures and syncope were not significantly increased in the intensive group, the STEP trial did show a slightly higher rate of symptomatic hypotension. Residents must balance cardiovascular benefits with iatrogenic risks by monitoring for orthostatic hypotension, carefully choosing agents (e.g., initiating at lower doses, avoiding agents with high orthostatic potential like alpha-blockers), and monitoring renal function and electrolytes, especially when using diuretics or RAAS inhibitors.
The STEP trial included older patients (aged 60-80 years) and demonstrated benefits similar to the SPRINT trial. However, unlike SPRINT, STEP included a substantial proportion of patients with a prior history of stroke. How does this inclusion alter the landscape of secondary stroke prevention compared to previous trials like SPS3?
Key Response
SPRINT excluded patients with prior stroke, leaving a gap in evidence for intensive BP control in this high-risk group. The SPS3 trial targeted <130 mm Hg but was restricted to patients with lacunar strokes. STEP provides broader evidence that intensive SBP control (<130 mm Hg) is highly beneficial and safe in an older population with a higher baseline epidemiological risk of stroke (an East Asian cohort), reinforcing the push for intensive targets in comprehensive secondary stroke prevention.
The STEP trial excluded patients with severe frailty or a life expectancy of less than 3 years. How do you integrate the intensive BP targets from STEP into shared decision-making for a typical 78-year-old clinic patient who exhibits mild-to-moderate frailty and polypharmacy, who would not have qualified for the trial?
Key Response
Attendings must balance trial evidence with real-world geriatric complexities. While STEP proves chronological age alone shouldn't preclude intensive targets, biological age and frailty dictate actual patient risk. In real-world settings, polypharmacy and frailty exponentially increase the risk of orthostasis and falls. The attending must teach how to individualize targets, perhaps starting with a standard target and carefully titrating towards the intensive target only if well-tolerated and aligned with the patient's goals of care.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STEP trial utilized a smartphone-based app and home blood pressure monitoring (HBPM) for titration, alongside office measurements. How does this methodological integration of digital health tools affect the internal validity and external generalizability of the trial's findings compared to traditional trials relying solely on automated office blood pressure (AOBP)?
Key Response
Incorporating HBPM and app-based data improves ecological validity, reduces the white-coat effect, and likely enhances medication adherence, which strengthens internal validity. However, it introduces a potential selection bias by favoring technologically literate or better-resourced older adults, limiting external generalizability to less connected populations. Furthermore, comparing STEP's outcomes directly to SPRINT requires adjusting for the systematic differences between HBPM and AOBP modalities.
The STEP trial was an open-label study with blinded end-point assessment (PROBE design). What are the specific threats to validity regarding the ascertainment of subjective components within the composite primary outcome, and how could investigator or performance bias have influenced the results?
Key Response
In a PROBE design, patients and treating physicians are aware of the treatment assignment. A tough reviewer would flag that this lack of blinding can lead to performance bias, where physicians might aggressively modify non-BP risk factors (like statin initiation) differently between groups. Furthermore, subjective components of the composite primary outcome, such as the decision to hospitalize for acute decompensated heart failure or unstable angina, can be subtly influenced by the physician's knowledge of the patient's blood pressure target.
The 2017 ACC/AHA guidelines recommend a target of <130/80 mm Hg for ambulatory older adults, whereas the 2018 ESC/ESH guidelines generally recommend a less stringent target of <140/90 mm Hg for those >65 years. Based on the STEP trial's efficacy and safety data, does this evidence provide sufficient strength to harmonize international guidelines toward the stricter ACC/AHA target?
Key Response
The STEP trial strongly supports the 2017 ACC/AHA <130 mm Hg recommendation, demonstrating a clear reduction in major adverse cardiovascular events (Level of Evidence: B-R or A) without a prohibitive increase in severe adverse events in the 60-80 age group. A guideline committee must weigh this robust data from an East Asian population against older concerns of falls and hypoperfusion, potentially prompting European and other international guidelines to lower their standard targets for fit older adults, bridging the global discrepancy in geriatric hypertension management.
Clinical Landscape
Noteworthy Related Trials
HYVET
Tested
Indapamide with or without perindopril (target BP < 150/80 mm Hg)
Population
Patients >= 80 years old with sustained hypertension
Comparator
Placebo
Endpoint
Fatal or nonfatal stroke
ACCORD BP Trial
Tested
Intensive BP control (target SBP < 120 mm Hg)
Population
Patients with type 2 diabetes and high CV risk
Comparator
Standard BP control (target SBP < 140 mm Hg)
Endpoint
Composite of nonfatal MI, nonfatal stroke, or CV death
SPRINT Trial
Tested
Intensive BP control (target SBP < 120 mm Hg)
Population
Adults >= 50 years with high CV risk, without diabetes
Comparator
Standard BP control (target SBP < 140 mm Hg)
Endpoint
Composite of MI, acute coronary syndrome, stroke, heart failure, or CV death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis